基于血清酪氨酸酶抗体水平探讨补肾Ⅰ号方治疗白癜风临床研究

Clinical efficacy of Bushen Ⅰ prescription in the treatment of vitiligo based on serum tyrosinase antibody level

目的观察补肾Ⅰ号方治疗白癜风的临床疗效及对血清酪氨酸酶抗体IgM(TYR-IgM)、酪氨酸酶抗体IgG(TYR-IgG)水平的影响。方法采用前瞻性、开放性随机对照研究设计。选取60例在我院门诊及住院治疗的白癜风患者,研究时间自2017年06月至2018年12月,对每例患者进行编号,随后按随机数字表法分为A组(白癜风丸口服,n=30)、B组(补肾Ⅰ号方口服,n=30)。比较治疗前、后两组患者临床疗效,血清TYR-IgM、TYR-IgG水平,白癜风活动性评分及皮肤病生活质量指数(DLQI)评分。结果B组疗法相较于A组,可有效降低白癜风患者血清中TYR-IgM、TYR-IgG水平,并改善白癜风活动性评分及皮肤病生活质量指数(DLQI)评分(P<0.05),差异有统计学意义。结论补肾Ⅰ号方可有效改善白癜风患者病情,临床疗效满意,但其系统生物学机制仍需进一步研究。

Objective This study was designed to observe the clinical efficacy of Bushen I prescription(BSⅠ)for treating vitiligo and its effect on serum tyrosinase antibody IgM(TYR-IgM)and IgG(TYR-IgG)levels.Methods A prospective,open randomized controlled trial design was applied.Sixty vitiligo patients who were out-hospitalized and hospitalized in our hospital were selected.The study time was from June 2017 to December 2018.Each patient was numbered.And then,according to the random number table method,Sixty patients were divided into group A(oral Baidianfeng wan,n=30),group B(oral BS I,n=30).The clinical efficacy,serum TYR-IgM,TYR-IgG levels,vitiligo activity score and skin disease quality of life index(DLQI)scores were compared between the two groups before and after treatment.Results Compared with group A,group B therapy can effectively reduce the levels of TYR-IgM and TYR-IgG in serum of vitiligo patients,and ameliorate vitiligo activity score and DLQI score(P<0.05).Conclusion BS I can effectively improve the condition of patients with vitiligo,and the clinical effect is satisfactory,but its systemic biological mechanism still needs further study.